Pllr Search With Doc Label

Summary

Miriam Dinatale and Jane Liedtka from CDER's Office of New Drugs address key considerations and best practices for Farrokh Sohrabi, CDER Office of New Drugs, provides an overview of Physician Dr. Eric Brodsky, Associate Director of the Eric Brodsky, CDER Office of New Drugs, shares insights on the physician Ann Marie Trentacosti, CDER Office of New Drugs (OND), discusses considerations for Joseph A. Grillo, CDER Office of Translational Sciences, provides an overview of key This webinar provided an overview of FDA's new The number of submissions to the FDA involving physiologically-based pharmacokinetic (PBPK) modeling has increased ... Jessica Greenbaum and Ruby Wu from the Office of Therapeutic Biologics and Biosimilars (OTBB) in CDER's Office of New Drugs ... A presenter covers how industry currently manages Structured Product Adam Kroetsch from CDER's Office of Program and Strategic Analysis provides an introduction to the use of structured product ... This presentation provided a list of required data when requesting a labeler code from FDA and identified common labeler ...